Figure 2.

Panel A: Rates of VR20 declined as caffeine k_elim (P=0.0001), antipyrine k_elim (P=0.0002), antipyrine Cl (P=0.0002), cholate Cl_oral (P=0.0003), cholate shunt (P=0.0001), MEGX_15min (P=0.01), MEGX_30min (P=0.005), methionine breath test (P=0.02), and perfused hepatic mass (P=0.01) worsened. Panel B: Rates of SVR declined as caffeine k_elim (P=0.002), antipyrine k_elim (P=0.002), antipyrine Cl (P=0.002), cholate Cl_oral (P=0.003), cholate shunt (P=0.002), methionine breath test (P=0.04), and perfused hepatic mass (P=0.01), MEGX_15min (P=0.09), and MEGX_30min (P=0.07) worsened. Cholate k_elim, cholate Cl_iv, and galactose elimination capacity, which primarily assess total hepatic blood flow, failed to correlate with either VR20 or SVR (not shown). Abbreviations: Q, quartile; QLFT, quantitative test of liver function; Caff k, rate constant of elimination of caffeine; AP k, rate constant of elimination of antipyrine; AP Cl, clearance of antipyrine; MEGX 15, concentration of monoethylglycylxylidide 15 minutes after administration of lidocaine; MEGX 30, concentration of monoethylglycylxylidide 30 minutes after administration of lidocaine; CA Clo, clearance of orally administered [2,2,4,4-²H] cholate; CA Shunt, cholate shunt; GEC, galactose elimination capacity; MBT, methionine breath test; PHM, perfused hepatic mass